Immunotherapy targeting the HPA axis in Alzheimer's disease
针对阿尔茨海默病 HPA 轴的免疫疗法
基本信息
- 批准号:10846355
- 负责人:
- 金额:$ 128.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-15 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Summary
Psychological stress and hypothalamic-pituitary-adrenal (HPA) axis dysfunction play a role in many disorders including
Alzheimer’s disease (AD), major depression, metabolic syndrome, and sarcopenia. Chronic high levels of stress and
elevated corticosteroids are also hypothesized to act as “accelerants” of many age-associated diseases and phenotypes.
Further, numerous studies report an association between increased stress and HPA axis dysfunction with increased rates
of cognitive decline and hippocampal and brain atrophy in late-life dementia. Our interest in the HPA axis stemmed from
rodent model data implicating psychological stress, corticotropin-releasing hormone/factor (CRH/CRF), and
corticosterone, as factors that impact amyloid and tau pathology and age-associated declines in cognitive function.
Indeed, suppression of the HPA axis theoretically represents a unique therapeutic strategy in AD, as it has been implicated
in regulating the underlying Aβ and tau proteinopathies and independently affecting, presumably through corticosteroid
excess, brain atrophy and cognitive decline. Unfortunately, testing the role of HPA axis in AD and cognitive aging, has been
hindered by the lack of small molecule therapeutics that effectively suppress HPA axis activation in humans. As an
alternative to small molecule approaches, we have successfully developed a picomolar affinity IgG1 monoclonal antibody
(mAb) targeting CRF (anti-CRF mAb, CTRND05) that dose-dependently blocks stress-induced increases in corticosterone,
and can rapidly reverse select Cushingoid phenotypes in mice overexpressing CRF. Metabolic and immunologic studies
reveal numerous effects consistent with long-lasting suppression of the HPA-axis; multi-organ transcriptomic studies
shows robust regulation of numerous genes that may mediate the physiologic effects of CTRND05. We hypothesize that
passive immunotherapy targeting CRF represents a novel, translatable, therapeutic approach to AD and possibly many
other disorders. Through pleiotropic actions, anti-CRF immunotherapy may slow the development of Aβ and tau
pathologies as well as brain atrophy and cognitive decline. In this proposal, we will systematically and rigorously evaluate
the therapeutic potential of this anti-CRF immunotherapy in appropriate preclinical models and develop companion
theragnostic biomarkers. As CRF is completely conserved between humans and mice, and is present at similar
concentrations, positive results from these studies will provide the rationale for testing of a humanized high affinity anti-
CRF mAb for therapeutic benefit in humans.
总结
心理应激和下丘脑-垂体-肾上腺(HPA)轴功能障碍在许多疾病中发挥作用,包括
阿尔茨海默病(AD)、重度抑郁症、代谢综合征和肌肉减少症。长期的高度压力和
还假设升高的皮质类固醇充当许多年龄相关疾病和表型的“促进剂”。
此外,许多研究报告了压力增加和HPA轴功能障碍之间的关联,
老年痴呆症患者认知能力下降、海马体和脑萎缩。我们对HPA轴的兴趣源于
涉及心理应激、促肾上腺皮质激素释放激素/因子(CRH/CRF)和
皮质酮,作为影响淀粉样蛋白和tau病理学以及与年龄相关的认知功能下降的因素。
事实上,HPA轴的抑制理论上代表了AD的独特治疗策略,因为它已经被证明是一种有效的治疗方法。
调节潜在的Aβ和tau蛋白病,并独立影响,可能是通过皮质类固醇
过量,脑萎缩和认知能力下降。不幸的是,测试HPA轴在AD和认知老化中的作用,
由于缺乏有效抑制人类HPA轴活化的小分子治疗剂而受阻。作为
作为小分子方法的替代,我们成功地开发了皮摩尔亲和力的IgG 1单克隆抗体,
(mAb)靶向CRF(抗CRF mAb,CTRND 05),其剂量依赖性地阻断应激诱导的皮质酮增加,
并且可以在过表达CRF的小鼠中快速逆转选择性库欣样蛋白表型。代谢和免疫学研究
揭示了与HPA轴的长期抑制一致的许多效应;多器官转录组学研究
显示了对许多可能介导CTRND 05生理效应的基因的稳健调节。我们假设
针对CRF的被动免疫疗法代表了一种新的、可转化的治疗AD的方法,
其他疾病。通过多效性作用,抗CRF免疫治疗可减缓Aβ和tau蛋白的发展。
病理学以及脑萎缩和认知能力下降。在这份提案中,我们将系统地、严格地评估
这种抗CRF免疫疗法在适当的临床前模型中的治疗潜力,
诊断学生物标志物。由于CRF在人类和小鼠之间完全保守,并且以相似的浓度存在,
这些研究的阳性结果将为测试人源化高亲和力抗-
CRF mAb用于人类治疗获益。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JENNIFER Lynn BIZON其他文献
JENNIFER Lynn BIZON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JENNIFER Lynn BIZON', 18)}}的其他基金
Mechanisms and therapeutic potential of vagus nerve stimulation in aging and Alzheimer’s disease
迷走神经刺激在衰老和阿尔茨海默病中的机制和治疗潜力
- 批准号:
10209090 - 财政年份:2021
- 资助金额:
$ 128.37万 - 项目类别:
Effects of cannabis on age-related cognitive decline and Alzheimers disease pathology
大麻对与年龄相关的认知能力下降和阿尔茨海默病病理学的影响
- 批准号:
10316617 - 财政年份:2021
- 资助金额:
$ 128.37万 - 项目类别:
Effects of cannabis on age-related cognitive decline and Alzheimers disease pathology
大麻对与年龄相关的认知能力下降和阿尔茨海默病病理学的影响
- 批准号:
10633300 - 财政年份:2021
- 资助金额:
$ 128.37万 - 项目类别:
Effects of cannabis on age-related cognitive decline and Alzheimers disease pathology
大麻对与年龄相关的认知能力下降和阿尔茨海默病病理学的影响
- 批准号:
10469575 - 财政年份:2021
- 资助金额:
$ 128.37万 - 项目类别:
Clinical and Translational Pre-doctoral training in Alzheimer's Disease and Related Dementias
阿尔茨海默病和相关痴呆症的临床和转化博士前培训
- 批准号:
10475693 - 财政年份:2018
- 资助金额:
$ 128.37万 - 项目类别:
Clinical and Translational Pre-doctoral training in Alzheimer's Disease and Related Dementias
阿尔茨海默病和相关痴呆症的临床和转化博士前培训
- 批准号:
10228736 - 财政年份:2018
- 资助金额:
$ 128.37万 - 项目类别:
2RO1AG029421 Neural Mechanisms of Age-related cognitive decline
2RO1AG029421 与年龄相关的认知能力下降的神经机制
- 批准号:
8852384 - 财政年份:2014
- 资助金额:
$ 128.37万 - 项目类别:
Neural Mechanisms of Cognitive Decline in Aging
衰老过程中认知能力下降的神经机制
- 批准号:
9250037 - 财政年份:2007
- 资助金额:
$ 128.37万 - 项目类别:
Basal forebrain and cognitive aging: Novel experimental and theraptutic avenues
基底前脑和认知衰老:新的实验和治疗途径
- 批准号:
8180233 - 财政年份:2007
- 资助金额:
$ 128.37万 - 项目类别:
Basal forebrain and cognitive aging: Novel experimental and theraptutic avenues
基底前脑和认知衰老:新的实验和治疗途径
- 批准号:
7627219 - 财政年份:2007
- 资助金额:
$ 128.37万 - 项目类别:
相似国自然基金
靶向PARylation介导的DNA损伤修复途径在恶性肿瘤治疗中的作用与分子机制研究
- 批准号:82373145
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
诱导性多能干细胞rDNA区基因打靶在线粒体视神经病中的治疗研究
- 批准号:81970829
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
Pre-targeting/Click反应介导的自体循环干细胞在心脏缺血损伤修复中的应用及机制研究
- 批准号:81873493
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
以IGF2/IGF1R与SYT/SSX1为靶点治疗滑膜肉瘤的实验研究
- 批准号:81102033
- 批准年份:2011
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
基于ZFN/phiC31系统的新型基因打靶技术的建立(果蝇)
- 批准号:31171278
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Fragment to small molecule hit discovery targeting Mycobacterium tuberculosis FtsZ
针对结核分枝杆菌 FtsZ 的小分子片段发现
- 批准号:
MR/Z503757/1 - 财政年份:2024
- 资助金额:
$ 128.37万 - 项目类别:
Research Grant
Targeting metabolism to improve the host response to peritoneal dialysis
靶向代谢以改善宿主对腹膜透析的反应
- 批准号:
MR/Y013816/1 - 财政年份:2024
- 资助金额:
$ 128.37万 - 项目类别:
Research Grant
Targeting Inhibitory kappa B kinase alpha (IKKalpha): a new treatment paradigm for inflammatory-driven cancers
靶向抑制性 kappa B 激酶 alpha (IKKalpha):炎症驱动的癌症的新治疗范例
- 批准号:
MR/Y015479/1 - 财政年份:2024
- 资助金额:
$ 128.37万 - 项目类别:
Research Grant
Development of a novel cancer immunotherapy model targeting human macrophages
开发针对人类巨噬细胞的新型癌症免疫治疗模型
- 批准号:
24K18516 - 财政年份:2024
- 资助金额:
$ 128.37万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Designing Rational Combinations to Improve CAR T Cell Therapy for Prostate Cancer
设计合理的组合以改善前列腺癌的 CAR T 细胞疗法
- 批准号:
10752046 - 财政年份:2024
- 资助金额:
$ 128.37万 - 项目类别:
Greatwall in replication stress/DNA damage responses and oral cancer resistance
长城在复制应激/DNA损伤反应和口腔癌抵抗中的作用
- 批准号:
10991546 - 财政年份:2024
- 资助金额:
$ 128.37万 - 项目类别:
Genetic targeting of a synthetic dye for voltage imaging of cerebellar Purkinje neurons during a tongue grasping task
一种合成染料的基因靶向,用于抓取舌头任务期间小脑浦肯野神经元的电压成像
- 批准号:
23K27147 - 财政年份:2024
- 资助金额:
$ 128.37万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
- 批准号:
24K19237 - 财政年份:2024
- 资助金额:
$ 128.37万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Optimisation of small molecule inhibitors for effective targeting of phospholipase C gamma in T-cell lymphoma
优化小分子抑制剂以有效靶向 T 细胞淋巴瘤中的磷脂酶 C γ
- 批准号:
MR/Y503344/1 - 财政年份:2024
- 资助金额:
$ 128.37万 - 项目类别:
Research Grant
Targeting soluble guanylate cyclase as a novel strategy to treat and prevent cardiac arrhythmias: efficacy and mechanisms
靶向可溶性鸟苷酸环化酶作为治疗和预防心律失常的新策略:功效和机制
- 批准号:
MR/Y003594/1 - 财政年份:2024
- 资助金额:
$ 128.37万 - 项目类别:
Research Grant